CR10799A - Derivados de metastina y sus usos - Google Patents

Derivados de metastina y sus usos

Info

Publication number: CR10799A
Authority: CR; Costa Rica
Prior art keywords: metastinine; derivatives; metastinine derivatives
Prior art date: 2006-10-25

Application number

CR10799A

Other languages

English (en)

Inventor

Taiji Asami

Naoki Nishizawa

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-25

Filing date

2009-05-15

Publication date

2009-06-09

2009-05-15 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2009-06-09 Publication of CR10799A publication Critical patent/CR10799A/es

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Zoology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Biochemistry (AREA)
Toxicology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)

CR10799A 2006-10-25 2009-05-15 Derivados de metastina y sus usos CR10799A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2006290536		2006-10-25
JP2007021387		2007-01-31
JP2007221911		2007-08-28

Publications (1)

Publication Number	Publication Date
CR10799A true CR10799A (es)	2009-06-09

Family

ID=38925530

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR10799A CR10799A (es)	2006-10-25	2009-05-15	Derivados de metastina y sus usos

Country Status (33)

Country	Link
US (2)	US7786083B2 (es)
EP (1)	EP2081955B1 (es)
JP (2)	JP2010507565A (es)
KR (1)	KR101424306B1 (es)
AR (1)	AR063367A1 (es)
AU (1)	AU2007309969B2 (es)
BR (1)	BRPI0717441B8 (es)
CA (1)	CA2667537C (es)
CL (1)	CL2007003053A1 (es)
CR (1)	CR10799A (es)
CY (1)	CY1116627T1 (es)
DK (1)	DK2081955T3 (es)
EC (1)	ECSP099279A (es)
ES (1)	ES2539430T3 (es)
GE (1)	GEP20125568B (es)
HR (1)	HRP20150819T1 (es)
HU (1)	HUE025291T2 (es)
IL (1)	IL198046A (es)
JO (1)	JO3048B1 (es)
MA (1)	MA30887B1 (es)
ME (1)	ME00786B (es)
MX (1)	MX2009004148A (es)
MY (1)	MY145975A (es)
NO (1)	NO341584B1 (es)
NZ (1)	NZ576375A (es)
PE (1)	PE20081469A1 (es)
PL (1)	PL2081955T3 (es)
PT (1)	PT2081955E (es)
RS (1)	RS54083B1 (es)
SI (1)	SI2081955T1 (es)
TN (1)	TN2009000140A1 (es)
TW (1)	TWI404726B (es)
WO (1)	WO2008050897A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004063221A1 (ja)	2002-12-26	2004-07-29	Takeda Pharmaceutical Company Limited	メタスチン誘導体およびその用途
WO2006001499A2 (en) *	2004-06-25	2006-01-05	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
AR058584A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
US8404643B2 (en)	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090099334A1 (en) *	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
JP5279021B2 (ja) *	2006-04-26	2013-09-04	国立大学法人京都大学	Ｇｐｒ５４アゴニスト活性を有する新規化合物
JO3048B1 (ar)	2006-10-25	2016-09-05	Takeda Pharmaceuticals Co	مشتقات متاستين واستخدامها
US8110639B2 (en) *	2006-11-17	2012-02-07	Solvay Advanced Polymers, L.L.C.	Transparent and flame retardant polysulfone compositions
US20110118172A1 (en) *	2008-04-24	2011-05-19	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
EP2275433B1 (en) *	2008-04-30	2017-06-07	Kyoto University	Metastin derivative and use thereof
WO2010013762A1 (ja)	2008-07-30	2010-02-04	武田薬品工業株式会社	メタスチン誘導体およびその用途
US8716228B2 (en)	2009-05-27	2014-05-06	Yeda Research And Development Co. Ltd.	GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities
EP2585091B1 (en) *	2010-06-25	2014-09-10	Takeda Pharmaceutical Company Limited	Sustained-release formulation comprising a metastin derivative
EP2755690B1 (en)	2011-08-04	2020-04-01	Merck Sharp & Dohme B.V.	Kisspeptide-pentasaccharide conjugates
CA2915055C (en) *	2013-06-12	2021-07-20	Merck Patent Gmbh	Hydroxyethylene derivatives for the treatment of arthrosis
WO2015112703A1 (en) *	2014-01-22	2015-07-30	The Johns Hopkins University	Compositions and methods for treating diabetes
JP6253146B2 (ja) *	2014-02-04	2017-12-27	国立大学法人山口大学	新規なペプチド誘導体及びこれを含有する医薬
CN107428803A (zh) *	2015-02-08	2017-12-01	耶路撒冷希伯来大学伊萨姆研究发展有限公司	用于治疗恶性增殖性疾病的肽
CN116813705A (zh) *	2017-07-05	2023-09-29	凯惠科技发展(上海)有限公司	一种肽类化合物、其应用及含其的组合物
TWI795462B (zh) *	2017-11-17	2023-03-11	日商鹽野義製藥股份有限公司	光安定性及溶出性優異的醫藥製劑
JP2023521388A (ja) *	2020-04-08	2023-05-24	ラトガース，ザステートユニバーシティオブニュージャージー	脂肪肝疾患に対する修飾キスペプチン受容体作用薬
WO2025217074A1 (en) *	2024-04-08	2025-10-16	Radionetics Oncology, Inc.	Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL74827A (en)	1984-05-21	1989-06-30	Salk Inst For Biological Studi	Peptides active as gnrh antagonists and pharmaceutical compositions containing them
MX9100717A (es)	1990-08-24	1992-04-01	Syntex Inc	Antagonistas de la bradiquinina
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
CA2229201A1 (en)	1995-10-19	1997-04-24	Satoshi Sasaki	Quinoline derivatives, their production and use
JPH09169735A (ja)	1995-10-19	1997-06-30	Takeda Chem Ind Ltd	キノリン誘導体、その製造法および用途
AU2382097A (en)	1996-04-19	1997-11-12	Novo Nordisk A/S	Compounds with growth hormone releasing properties
CA2283299A1 (en)	1997-03-07	1998-09-11	Human Genome Sciences, Inc.	186 human secreted proteins
JP4486187B2 (ja)	1998-10-27	2010-06-23	武田薬品工業株式会社	新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
US6528054B1 (en)	1998-12-28	2003-03-04	Corixa Corporation	Compositions and methods for the therapy and diagnosis of breast cancer
MXPA01013367A (es)	1999-06-28	2002-07-02	Basf Ag	Metodo para la prevencion del crecimiento tumoral.
US6638906B1 (en)	1999-12-13	2003-10-28	Nobex Corporation	Amphiphilic polymers and polypeptide conjugates comprising same
AU1889101A (en)	1999-12-17	2001-06-25	Takeda Chemical Industries Ltd.	Process for producing kiss-1 peptide
AU2001261007A1 (en)	2000-03-29	2001-10-08	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
WO2001075104A1 (fr)	2000-03-30	2001-10-11	Takeda Chemical Industries, Ltd.	Nouvelle proteine, adn codant pour celle-ci, et son procede de production
US7834141B1 (en)	2000-03-31	2010-11-16	Theresa Siler-Khodr	Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy
RU2311920C2 (ru)	2000-09-20	2007-12-10	Корикса Корпорейшн	Композиции и способы для лечения и диагностики рака легких
JP2003026601A (ja)	2000-11-29	2003-01-29	Takeda Chem Ind Ltd	医薬組成物およびその製造法
JP2002320496A (ja)	2001-02-26	2002-11-05	Takeda Chem Ind Ltd	新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ
WO2002085399A1 (fr)	2001-04-20	2002-10-31	Takeda Chemical Industries, Ltd.	Preparations contenant un peptide
WO2002092829A1 (en)	2001-05-17	2002-11-21	Takeda Chemical Industries, Ltd.	Process for producing peptide
DE60219645T2 (de) *	2001-09-19	2007-08-09	Takeda Pharmaceutical Co. Ltd.	Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft
AU2003201854A1 (en) *	2002-01-11	2003-07-30	Takeda Chemical Industries, Ltd.	PROCESS FOR PRODUCING KiSS-1 PEPTIDE
JP2003300906A (ja)	2002-04-12	2003-10-21	Daiichi Fine Chemical Co Ltd	がん転移抑制因子の安定化
AU2003272964A1 (en) *	2002-10-09	2004-05-04	Kyowa Hakko Kogyo Co., Ltd.	Remedy for hormone-dependent cancer
MXPA05004380A (es)	2002-10-25	2005-11-23	Paradigm Therapeutics Ltd	Mamiferos gpr54 knock out y metodos de investigacion que los utilizan.
JP4804714B2 (ja)	2002-12-26	2011-11-02	武田薬品工業株式会社	メタスチン誘導体およびその用途
WO2004063221A1 (ja)	2002-12-26	2004-07-29	Takeda Pharmaceutical Company Limited	メタスチン誘導体およびその用途
US6800611B2 (en)	2003-01-06	2004-10-05	Takeda Chemical Industries, Ltd.	Metastin derivatives and their use
KR100595364B1 (ko)	2003-02-20	2006-07-03	재단법인 목암생명공학연구소	Ｌｋ8 단백질을 유효성분으로 포함하는 항암제
US7754220B2 (en) *	2003-03-12	2010-07-13	Takeda Pharmaceutical Company Limited	Methods of inhibiting secretion of follicle-stimulating hormone and testosterone
EP1464652A1 (en)	2003-04-02	2004-10-06	Institut National De La Sante Et De La Recherche Medicale (Inserm)	GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases
US20050002935A1 (en)	2003-04-17	2005-01-06	Vincent Ling	Use of B7-H3 as an immunoregulatory agent
US20050026224A1 (en)	2003-04-28	2005-02-03	Follettie Maximillian T.	Methods and compositions for modulating G-protein coupled receptor 54
WO2004101747A2 (en)	2003-05-07	2004-11-25	The General Hospital Corporation	Identification and use of gpr54 and its ligands for reproductive disorders and contraception
WO2004106289A1 (en)	2003-05-30	2004-12-09	Prozymex A/S	Protease inhibitors
CA2544473C (en)	2003-11-03	2013-08-13	Beijing Sunbio Biotech Co., Ltd.	A recombinant protein having an anti-cancer effect, its encoding gene and uses thereof
WO2005095973A2 (en)	2004-03-25	2005-10-13	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54)
WO2005117939A2 (en)	2004-04-23	2005-12-15	Applied Research Systems Ars Holding N.V.	Use of gpcr54 ligands for the treatment of infertility
WO2006001499A2 (en)	2004-06-25	2006-01-05	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
WO2007084211A2 (en)	2005-11-11	2007-07-26	The General Hospital Corporation	Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception
US8404643B2 (en)	2005-12-22	2013-03-26	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
AR058584A1 (es)	2005-12-22	2008-02-13	Takeda Pharmaceutical	Derivados de metastina y uso de los mismos
US20090093615A1 (en) *	2005-12-22	2009-04-09	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20090099334A1 (en) *	2005-12-22	2009-04-16	Takeda Pharmaceutical Company Limited	Metastin derivatives and use thereof
US20070244048A1 (en)	2006-03-20	2007-10-18	Marsh Donald J	Neuromedin U receptor agonists and uses thereof
US20100215637A1 (en) *	2006-03-28	2010-08-26	Biopharmica Ltd	Agent for the Treatment of Hormone-Dependent Disorders and Uses Thereof
JO3048B1 (ar)	2006-10-25	2016-09-05	Takeda Pharmaceuticals Co	مشتقات متاستين واستخدامها
CA2701612A1 (en)	2007-10-05	2009-04-09	Takeda Pharmaceutical Company Limited	Neuromedin u derivative
US20110118172A1 (en)	2008-04-24	2011-05-19	Takeda Pharmaceutical Company Limited	Metastin derivative and use thereof
EP2340047A1 (en)	2008-09-19	2011-07-06	Nektar Therapeutics	Polymer conjugates of kiss1 peptides

2007
- 2007-10-23 JO JOP/2007/0448A patent/JO3048B1/ar active
- 2007-10-23 TW TW096139608A patent/TWI404726B/zh not_active IP Right Cessation
- 2007-10-24 HR HRP20150819TT patent/HRP20150819T1/hr unknown
- 2007-10-24 GE GEAP200711265A patent/GEP20125568B/en unknown
- 2007-10-24 JP JP2009518179A patent/JP2010507565A/ja active Pending
- 2007-10-24 ME MEP-2009-130A patent/ME00786B/me unknown
- 2007-10-24 NZ NZ576375A patent/NZ576375A/en not_active IP Right Cessation
- 2007-10-24 WO PCT/JP2007/071169 patent/WO2008050897A1/en not_active Ceased
- 2007-10-24 PE PE2007001444A patent/PE20081469A1/es active IP Right Grant
- 2007-10-24 AU AU2007309969A patent/AU2007309969B2/en not_active Ceased
- 2007-10-24 US US11/977,477 patent/US7786083B2/en active Active
- 2007-10-24 EP EP20070830903 patent/EP2081955B1/en active Active
- 2007-10-24 ES ES07830903.6T patent/ES2539430T3/es active Active
- 2007-10-24 HU HUE07830903A patent/HUE025291T2/en unknown
- 2007-10-24 SI SI200731649T patent/SI2081955T1/sl unknown
- 2007-10-24 US US12/446,142 patent/US8765909B2/en not_active Expired - Fee Related
- 2007-10-24 CL CL200703053A patent/CL2007003053A1/es unknown
- 2007-10-24 RS RS20150413A patent/RS54083B1/sr unknown
- 2007-10-24 MY MYPI20091689A patent/MY145975A/en unknown
- 2007-10-24 PT PT78309036T patent/PT2081955E/pt unknown
- 2007-10-24 DK DK07830903.6T patent/DK2081955T3/da active
- 2007-10-24 BR BRPI0717441A patent/BRPI0717441B8/pt not_active IP Right Cessation
- 2007-10-24 AR ARP070104699A patent/AR063367A1/es active IP Right Grant
- 2007-10-24 PL PL07830903T patent/PL2081955T3/pl unknown
- 2007-10-24 KR KR1020097010545A patent/KR101424306B1/ko not_active Expired - Fee Related
- 2007-10-24 MX MX2009004148A patent/MX2009004148A/es active IP Right Grant
- 2007-10-24 CA CA2667537A patent/CA2667537C/en active Active
2009
- 2009-04-06 IL IL198046A patent/IL198046A/en active IP Right Grant
- 2009-04-15 TN TNP2009000140A patent/TN2009000140A1/fr unknown
- 2009-04-16 NO NO20091487A patent/NO341584B1/no unknown
- 2009-04-23 EC EC2009009279A patent/ECSP099279A/es unknown
- 2009-05-13 MA MA31868A patent/MA30887B1/fr unknown
- 2009-05-15 CR CR10799A patent/CR10799A/es unknown
2013
- 2013-01-11 JP JP2013004011A patent/JP5686825B2/ja not_active Expired - Fee Related
2015
- 2015-07-29 CY CY20151100668T patent/CY1116627T1/el unknown

Also Published As

Publication number	Publication date
CA2667537A1 (en)	2008-05-02
NO341584B1 (no)	2017-12-11
US20110059888A1 (en)	2011-03-10
TWI404726B (zh)	2013-08-11
AR063367A1 (es)	2009-01-21
PE20081469A1 (es)	2008-12-25
JO3048B1 (ar)	2016-09-05
US8765909B2 (en)	2014-07-01
CA2667537C (en)	2017-01-17
MY145975A (en)	2012-05-31
CY1116627T1 (el)	2017-03-15
HUE025291T2 (en)	2016-02-29
EP2081955A1 (en)	2009-07-29
GEP20125568B (en)	2012-07-10
DK2081955T3 (da)	2015-06-15
ME00786B (me)	2011-12-20
MX2009004148A (es)	2009-05-01
PL2081955T3 (pl)	2015-10-30
BRPI0717441B1 (pt)	2019-07-02
ECSP099279A (es)	2009-06-30
JP5686825B2 (ja)	2015-03-18
HK1130500A1 (en)	2009-12-31
AU2007309969B2 (en)	2012-04-19
NZ576375A (en)	2011-07-29
IL198046A0 (en)	2011-08-01
JP2010507565A (ja)	2010-03-11
MA30887B1 (fr)	2009-11-02
TN2009000140A1 (en)	2010-10-18
HRP20150819T1 (hr)	2015-09-11
TW200823232A (en)	2008-06-01
KR20090090315A (ko)	2009-08-25
KR101424306B1 (ko)	2014-08-01
PT2081955E (pt)	2015-07-10
SI2081955T1 (sl)	2015-06-30
RS54083B1 (sr)	2015-10-30
US20090215700A1 (en)	2009-08-27
WO2008050897A1 (en)	2008-05-02
IL198046A (en)	2014-06-30
US7786083B2 (en)	2010-08-31
ES2539430T3 (es)	2015-06-30
AU2007309969A1 (en)	2008-05-02
NO20091487L (no)	2009-07-07
EP2081955B1 (en)	2015-05-06
BRPI0717441B8 (pt)	2021-05-25
AU2007309969A2 (en)	2009-06-04
BRPI0717441A2 (pt)	2013-11-19
JP2013075913A (ja)	2013-04-25
CL2007003053A1 (es)	2008-08-08

Publication	Publication Date	Title
CR10466A (es)	2009-03-02	Anticuerpos e inmunoconjugados y sus usos
DOP2007000084A (es)	2007-12-31	Derivados de dihidropirazolopirimidinona
CR10815A (es)	2009-08-12	Nuevos derivados de isoquinolina e isoquinolinona sustituidos
ATE483711T1 (de)	2010-10-15	Spiroindolinonderivate
ATE469905T1 (de)	2010-06-15	Pyridopyrimidinonderivate
ATE512135T1 (de)	2011-06-15	Spiroindolinonderivate
BRPI0813707A2 (pt)	2014-12-30	Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt)	2015-05-05	Derivados de isoxazol-piridina
BRPI0809992A2 (pt)	2014-10-14	Derivados de pirrolopirimidina
BRPI0813966A2 (pt)	2015-01-06	Usos de mdl-1
DK2035394T3 (da)	2009-10-05	2-pyrazincarboxamidderivater
BRPI0812155A2 (pt)	2019-09-24	derivados de espiroindolinona
BRPI0920927A2 (pt)	2019-09-24	derivados de azaquinolinona e usos dos mesmos
BRPI0817935A2 (pt)	2015-04-07	Derivados de biarila
DK2081955T3 (da)	2015-06-15	Metastinderivater og anvendelse deraf
EP1993810A4 (en)	2011-03-02	MULTI LINE LINE EMBOSSING APPARATUS
DE602007012130D1 (de)	2011-03-03	Modifizierte flavin-adenin-dinucleotid-abhängige glucose-dehydrogenase
BRPI0814236A2 (pt)	2015-01-06	Derivados de quinazolinamida
BRPI0812518A2 (pt)	2015-03-31	Derivados de indazolamida
HRP20141261T1 (xx)	2015-03-13	Spojevi tioninija i njihove uporabe
CR10809A (es)	2009-06-25	Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0806538A2 (pt)	2014-04-22	Derivados de glicinamida de espiropiperidina
DK2086968T3 (da)	2012-03-19	5-hydroxymethyl-oxazolidin-2-on-derivater
BRPI0817844A2 (pt)	2015-04-07	Derivados de 3-alcóxi-1-fenilpirazol e pesticidas
BRPI0814718A2 (pt)	2015-02-24	Derivados de isoxazol-imidazol